Migraine

The Pharmacy Times® Migraine Resource Center is a comprehensive resource for clinical news and expert insights on treatments for migraine headaches, which can cause severe throbbing pain or a pulsing sensation.

Erenumab Is Well Tolerated for up to 12 Months, Study Results Show

May 19, 2022

Article

Analysis finds that reported adverse events rarely led to the discontinuation of therapy when used as a migraine prophylaxis.

Excessive Consumption of Caffeine, Chocolate May Trigger Migraine Headaches

May 11, 2022

Article

Lifestyle-related factors, including food consumption, may significantly increase the chance of triggering a migraine headache.

Daily OTC Pearl: OTC Migraine Relief

May 02, 2022

Article

Nonprescription migraine pain reliever combines acetaminophen, aspirin, and caffeine to relieve migraine pain.

New Migraine Treatments Provide More Options for Easing, Preventing Symptoms

April 28, 2022

Article

Pharmacists can potentially improve the health and quality of life of millions of people by staying up to date with advancements in migraine treatments.

Fremanezumab Effective in Migraine Patients With Inadequate Response to Other Treatments

April 26, 2022

Article

Fremanezumab is the second FDA-approved preventive migraine treatment that blocks the activity of calcitonin gene-related peptide.

Eptinezumab Found to Lower Severity, Frequency of Migraine Headache Days

April 18, 2022

Article

Eptinezumab is a calcitonin gene-related peptide antagonist FDA-approved for the preventive treatment of migraine.

Physicians Recommend Plant-Based Diet to Ease Chronic Migraine Symptoms

April 12, 2022

Article

Study results show that an individual received little or no relief from doing yoga, eliminating certain foods, practicing medication, or taking prescribed medications.

Pharmacist Medication Insights: Fremanezumab-vfrm (Ajovy)

April 05, 2022

Video

Fremanezumab-vfrm is the second FDA-approved preventive migraine treatment that works by blocking the activity of calcitonin gene-related peptide.

Study Finds Reduction in Mean Monthly Migraine Days With Atogepant

March 28, 2022

Article

Patients in the atogepant 60 mg daily and 30 mg twice daily treatment arms of the study experienced a decrease of 6.88 and 7.46 monthly migraine days, respectively.

New Genetic Risk Factors Discovered in Migraine Study

March 22, 2022

Article

Previous research has shown that genetic factors contribute immensely to the risk of migraine.